coronaviruses (Biotechnology Information)
Structured Review

Coronaviruses, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coronavirus/pmc13126349-340-4-16?v=Biotechnology+Information
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "Broad-spectrum CRISPR-Cas13d-mediated strategy for combating human coronaviruses"
Article Title: Broad-spectrum CRISPR-Cas13d-mediated strategy for combating human coronaviruses
Journal: Molecular Therapy. Nucleic Acids
doi: 10.1016/j.omtn.2026.102888
Figure Legend Snippet: Schematic representation of the SARS-CoV-2 genome and crRNA design (A) The SARS-CoV-2 genome is a single-stranded, positive-sense RNA. Its first two-thirds comprise overlapping open reading frames, ORF1a and ORF1b, which are translated into 16 nonstructural proteins (nsp1–nsp16). The remaining genome encodes structural proteins—spike (S), envelope (E), membrane (M), and nucleocapsid (N)—along with 8 accessory proteins: ORF3a, 3c, 6, 7a, 7b, 8, and 9b. (B) crRNA design. A highly conserved 26-nucleotide target region was identified within the viral genome of human coronaviruses. Based on this, four overlapping 23-nucleotides crRNAs were designed indicated in red. (C) The designed crRNAs were aligned to the genomes of all seven human coronavirus species. Mismatches relative to the SARS-CoV-2 reference sequence are highlighted in red. Each number on the right represents a single mismatch, with the value indicating its position within the target sequence. The Cas13d seed region, critical for target recognition and cleavage, is marked with a green rectangle.
Techniques Used: Membrane, Sequencing
Figure Legend Snippet: Broad antiviral CRISPR-Cas13d-crRNA activity against human coronaviruses genome (A) Schematic diagrams illustrating the luciferase reporter system and the CRISPR-Cas13d expression cassette. The luciferase reporter gene is driven by the Pol II SV40 promoter, with the target sequence cloned downstream of the luciferase gene. The CRISPR-Cas13d expression cassette includes a U6 promoter for crRNA expression and an EF1α core promoter driving the expression of Cas13d and GFP. (B) Cas13d/crRNA construct was used to assess the inhibition of luciferase expression by various crRNAs. The tested crRNAs included those targeting the nsp12 genome (crRNA1-4) and a positive control Luc crRNA are shown relative to the Ctrl. Numbers above the bars indicate mismatch positions, with mismatches within the Cas13d seed region highlighted in green. Each number corresponds to a single mismatch. The data represent mean values (±SD) from three independent experiments each performed in duplicate. Statistical significance was analyzed using one-way ANOVA followed by Tukey’s multiple comparisons test. Significant differences are indicated (∗∗∗∗ p < 0.0001).
Techniques Used: CRISPR, Activity Assay, Luciferase, Expressing, Sequencing, Clone Assay, Construct, Inhibition, Positive Control
Figure Legend Snippet: Cas13d broadly inhibits the replication of human coronavirus replicons (A) Genomic diagrams of the replicons for SARS-CoV-2, SARS-CoV, and MERS-CoV. The replicons contain the 5′ and 3′ cis -acting signals required for viral replication, the large ORFs 1a and 1b encoding the replicase non-structural proteins (nsps), and the N gene, which is essential for efficient coronavirus RNA synthesis. The SARS-CoV-2 and SARS-CoV replicons, generated by in vitro ligation, also include a mNeonGreen (mNG) or GFP gene, respectively, positioned downstream of ORF1b and regulated by the S gene transcription regulatory sequence (TRS-M). (B) Inhibition of human coronavirus replicons by different crRNAs. Subgenomic mRNA (sgmRNA) levels were measured by RT-qPCR 2 days after transfection. A non-targeting crRNA (Ctrl) was included as a negative control. The horizontal axis shows the tested crRNAs, and the vertical axis shows relative viral RNA levels normalized to Ctrl. Data are presented as mean values (±SD) from three independent experiments each performed in duplicate. Statistical significance was determined using one-way ANOVA with Tukey’s multiple comparisons test, with significance levels indicated as ∗∗∗∗ p < 0.0001.
Techniques Used: Generated, In Vitro, Ligation, Sequencing, Inhibition, Quantitative RT-PCR, Transfection, Negative Control
Figure Legend Snippet: Cas13d inhibits the replication of various human coronavirus species when applied prior and post-infection (A) Relative subgenomic mRNA (sgmRNA) levels at 2 days post-infection are shown as the ratio of viral RNA measured in the presence of different crRNAs relative to the control (Ctrl). (B) The antiviral effects of 4 crRNAs were evaluated by quantifying genomic RNA (gRNA) in the supernatant every 24 h, up to the peak of infection, with each crRNA represented by a different color. Viral gRNA levels, including those treated with the control crRNA, were quantified by RT-qPCR. (C) Relative sgmRNA levels are shown for cells treated with different Cas13d/crRNAs. A non-targeting crRNA (Ctrl) is included as a negative control and set to 100%. The horizontal axis indicates the tested crRNAs, and the vertical axis shows relative viral RNA expression. Data represent mean ± SD from three independent experiments. Statistical significance is indicated as ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.
Techniques Used: Infection, Control, Quantitative RT-PCR, Negative Control, RNA Expression
Figure Legend Snippet: Cas13d-based SHERLOCK detection assay (A) Detection workflow. Infectious samples are collected, and RNA is extracted. The extracted RNA is reverse transcribed into DNA and then amplified using RPA. The amplified DNA is subsequently transcribed by T7 RNA polymerase to generate RNA targets. These RNA targets are recognized and cleaved by CRISPR-Cas13d guided by crRNA. Upon activation, Cas13d triggers collateral cleavage activity, degrading all surrounding RNAs, including fluorescent RNA reporters. Detection is performed using a lateral flow strip, where a single band indicates a negative result and two bands indicate a positive result. (B) Broad detection of human coronaviruses using Cas13d. Either crRNA2 or crRNA3 was used to broadly detect five human coronavirus species: SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-229E, and HCoV-NL63. C, control line; T, test line; NC, negative control. (C) Specificity testing against non-coronavirus respiratory viruses. Influenza A and Influenza B samples were tested under the same conditions used for SARS-CoV-2 detection. C, control line; T, test line; PC, positive control (SARS-CoV-2).
Techniques Used: Detection Assay, Reverse Transcription, Amplification, CRISPR, Activation Assay, Activity Assay, Stripping Membranes, Control, Negative Control, Positive Control
Figure Legend Snippet: Limit of detection of crRNA2 and crRNA3 for various human coronaviruses (A) Detection limit of crRNA2 and (B) crRNA3 for SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-229E, and HCoV-NL63. CRISPR-Cas13d, guided by a crRNA, specifically recognizes and cleaves the target RNA. Upon activation, Cas13d exhibits collateral cleavage activity, degrading nearby RNAs, including fluorescent reporters. Detection is carried out on a lateral flow strip: one band indicates a negative result, while two bands indicate a positive result. The assay was performed with serial dilutions (10-fold) ranging from 100 RNA copies down to 1 RNA copy. C, control line; T, test line; NC, negative control.
Techniques Used: CRISPR, Activation Assay, Activity Assay, Stripping Membranes, Control, Negative Control
Figure Legend Snippet: Mismatches of Bat-CoV relative to SARS-CoV-2 genome Positions 15–21 of the crRNA correspond to the seed region (underlined in the SARS-CoV-2 reference sequence), which differs for each crRNA. Nucleotides conserved across all four crRNA seed regions are highlighted in green in the SARS-CoV-2 sequence, whereas mismatches present in Bat-CoV are shown in bold red. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Bat-CoV, bat coronavirus.
Techniques Used: Sequencing
Figure Legend Snippet: Mismatches of other animal coronaviruses relative to SARS-CoV-2 genome Positions 15–21 of the crRNA correspond to the seed region (underlined in the SARS-CoV-2 reference sequence), which differs for each crRNA. Nucleotides conserved across all four crRNA seed regions are highlighted in green, whereas mismatches in the animal coronavirus sequences are shown in bold red. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; PRCV, porcine respiratory coronavirus; CCoV, canine coronavirus; PEDV, porcine epidemic diarrhea virus; SADS-CoV, swine acute diarrhea syndrome coronavirus; FCoV, feline coronavirus; FRCoV, ferret coronavirus; MHV, mouse hepatitis virus; RCoV, rat coronavirus; IBV, infectious bronchitis virus; PHEV, porcine hemagglutinating encephalomyelitis virus; CRCoV, canine respiratory coronavirus; BCoV, bovine coronavirus; ECoV, equine coronavirus; TCoV, turkey coronavirus; GCoV, goose coronavirus; DCoV, duck coronavirus; BWCoV, beluga whale coronavirus; WCoV, wigeon coronavirus; MHCoV, moorhen coronavirus; MCoV, munia coronavirus; THCoV, hrush coronavirus; PDCoV, porcine deltacoronavirus.
Techniques Used: Sequencing, Virus


